These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 16309958)

  • 1. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.
    Erman M; Seiden D; Zammit G; Sainati S; Zhang J
    Sleep Med; 2006 Jan; 7(1):17-24. PubMed ID: 16309958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramelteon for the treatment of insomnia.
    Borja NL; Daniel KL
    Clin Ther; 2006 Oct; 28(10):1540-55. PubMed ID: 17157111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
    Roth T; Seiden D; Sainati S; Wang-Weigand S; Zhang J; Zee P
    Sleep Med; 2006 Jun; 7(4):312-8. PubMed ID: 16709464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.
    Mini LJ; Wang-Weigand S; Zhang J
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):177-84. PubMed ID: 17996657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of ramelteon in a first-night model of transient insomnia.
    Zammit G; Schwartz H; Roth T; Wang-Weigand S; Sainati S; Zhang J
    Sleep Med; 2009 Jan; 10(1):55-9. PubMed ID: 18691937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.
    Roth T; Seiden D; Wang-Weigand S; Zhang J
    Curr Med Res Opin; 2007 May; 23(5):1005-14. PubMed ID: 17519067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
    Walsh JK; Thacker S; Knowles LJ; Tasker T; Hunneyball IM
    Sleep Med; 2009 Sep; 10(8):859-64. PubMed ID: 19345644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia.
    Wang-Weigand S; Watissée M; Roth T
    Sleep Med; 2011 Oct; 12(9):920-3. PubMed ID: 21925941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia.
    Walsh JK; Zammit G; Schweitzer PK; Ondrasik J; Roth T
    Sleep Med; 2006 Mar; 7(2):155-61. PubMed ID: 16260179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers.
    Farber RH; Burke PJ
    Curr Med Res Opin; 2008 Mar; 24(3):837-46. PubMed ID: 18257978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel.
    Zee PC; Wang-Weigand S; Wright KP; Peng X; Roth T
    Sleep Med; 2010 Jun; 11(6):525-33. PubMed ID: 20483660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study.
    Uchimura N; Ogawa A; Hamamura M; Hashimoto T; Nagata H; Uchiyama M
    Expert Rev Neurother; 2011 Feb; 11(2):215-24. PubMed ID: 21306209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramelteon: a novel approach in the treatment of insomnia.
    Reynoldson JN; Elliott E; Nelson LA
    Ann Pharmacother; 2008 Sep; 42(9):1262-71. PubMed ID: 18648020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.
    Zammit G; Erman M; Wang-Weigand S; Sainati S; Zhang J; Roth T
    J Clin Sleep Med; 2007 Aug; 3(5):495-504. PubMed ID: 17803013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.
    Karim A; Tolbert D; Cao C
    J Clin Pharmacol; 2006 Feb; 46(2):140-8. PubMed ID: 16432265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T; Soubrane C; Titeux L; Walsh JK;
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia.
    Richardson G; Wang-Weigand S
    Hum Psychopharmacol; 2009 Mar; 24(2):103-11. PubMed ID: 19090503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramelteon: a novel treatment for the treatment of insomnia.
    Wurtman R
    Expert Rev Neurother; 2006 Jul; 6(7):957-64. PubMed ID: 16831111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.